UC Davis MIND Institute researchers identify specific fetal antigens attacked …Science CodexUC Davis MIND Institute researchers have identified the specific antibodies that target fetal brain proteins in the blood of a subset of women whose children …
ScientistUC Davis MIND Institute researchers find exposure to maternal antibodies …EurekAlert (press release)Researchers with the UC Davis MIND Institute have found that prenatal exposure to specific combinations of antibodies found only in mothers o…
|
GSK taps UK firm for “beyond antibodies” drug technology
Yahoo! News A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby … LONDON (Reuters) – GlaxoSmithKline plans to exploit new technology from private British biotech company Immunocore to develop … |
|
GlaxoSmithKline taps UK firm for ‘beyond antibodies‘ drug technology
Economic Times GlaxoSmithKline taps UK firm for ‘beyond antibodies‘ drug technology. By Reuters | 9 Jul, 2013, 01.54PM IST. Post a Comment. 0. Share More. READ MORE ON » Roche | Oxford | Immunocore | GlaxoSmithKline | Genentech | drug technology | Cancer … |
|
GSK taps UK firm for “beyond antibodies” drug technology
Reuters LONDON | Tue Jul 9, 2013 4:20am EDT. LONDON (Reuters) – GlaxoSmithKline plans to exploit new technology from private British biotech company Immunocore to develop next-generation drugs against cancer that fight tumors in ways antibody-based drugs … |
|
Cell Therapeutics’ Pixuvri receives marketing approval from Italian Medicines …
pharmabiz.com The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have … |
CD30 expression in EBV+ DLBCL confers poor prognosisThe Oncology ReportAll were uniformly treated with rituximab plus chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), said Dr. Young of the department of hematopatho…
|
A survey of TREM2 antibodies reveals neuronal but not microglial staining in …
7thSpace Interactive (press release) Recently, two independent studies indicated a strong association between a rare rs75932628-T variant encoding non-functional R47H in the TREM2 gene and an increased risk for Alzheimer’s disease (AD). TREM2 expressed on monocytes/macrophages, … |
|
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma …
The Herald | HeraldOnline.com The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who … |
Market Access Granted In Italy For Aggressive Non-Hodgkin Lymphoma …Daily Markets (press release)CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cel…